As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Investing.com -- Le médicament rilzabrutinib, développé par Sanofi US Services Inc., a reçu la désignation de médicament orphelin le 20/02/2025 par la FDA pour le traitement de l'anémie hémolytique ...

Le groupe pharmaceutique Sanofi a annoncé mardi que la Food and Drug Administration , l'autorité sanitaire américaine, avait ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

Cette opération, qui avait suscité de vives inquiétudes lorsqu’elle avait été annoncée en octobre, entrera en vigueur «au ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Sanofi annonce que la FDA des Etats-Unis a accordé un examen prioritaire à la demande de licence supplémentaire de produit ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been accepted for priority review by the US Food and Drug Administration (FDA ...

Paris: Sanofi and CD&R have announced that they have signed the share purchase agreement in relation to the sale of a 50 ...

Regeneron Pharmaceuticals and Sanofi have won Food and Drug Administration priority review of their application seeking expanded approval of their blockbuster anti-inflammatory drug Dupixent for ...

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...